Drug intelligence / Profile preview

BTB-101

Development stage: Unknown
Lead developer: BTB Therapeutics
Modality: Small Molecules
Administration: Oral (anticipated Based On Small Molecule Class And Company Statements)

Overview

BTB-101 is a first-in-class, non-opioid small molecule analgesic developed by BTB Therapeutics. It acts as an antagonist of the alpha-2b adrenergic receptor (ADRA2B), providing potent analgesic effects comparable to opioids in preclinical models but without opioid-like side effects or dependence within the therapeutic range. Discovered through transcriptomics-based drug discovery, BTB-101 is being developed as a safer alternative for pain management, with potential applications in postoperative pain, cancer pain, and pruritus[1][2][6].

Brand names: ENDOPIN
Other names: BTB-101BTB101BTB 101ENDOPIN

Targets

ADRA2B (α2B)

Beyond the preview

Go deeper on BTB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTB-101.

Explore the full profile